Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • PI3K
    (174)
  • Akt
    (157)
  • Apoptosis
    (135)
  • mTOR
    (45)
  • NF-κB
    (36)
  • Autophagy
    (34)
  • Caspase
    (20)
  • ERK
    (20)
  • p38 MAPK
    (20)
  • Others
    (93)
TargetMol | Tags By Application
  • ELISA
    (8)
  • Functional assay
    (8)
  • FACS
    (7)
  • FCM
    (1)
TargetMol | Tags By Natures
  • Glycyrrhiza
    (4)
  • Cassia
    (3)
  • Isodon
    (3)
  • Centipeda
    (2)
  • Ophiopogon
    (2)
  • Phellodendron
    (2)
  • Polygala
    (2)
  • Solanum
    (2)
  • Sophora
    (2)
  • Acacia
    (1)
TargetMol | Tags By ResearchField
  • Cancer
    (129)
  • Inflammation
    (58)
  • Immune System
    (47)
  • Infection
    (26)
  • Metabolism
    (26)
  • Nervous System
    (23)
  • Cardiovascular System
    (20)
  • Endocrine system
    (7)
  • Respiratory System
    (2)
  • Others
    (2)
Filter
Search Result
Results for "

pi3k/akt

" in TargetMol Product Catalog.
  • Inhibitors & Agonists
    353
    TargetMol | All_Pathways
  • Compound Libraries
    4
    TargetMol | Compound_Libraries
  • Peptide Products
    11
    TargetMol | Peptide_Products
  • Inhibitory Antibodies
    8
    TargetMol | Inhibitory_Antibodies
  • PROTAC Products
    5
    TargetMol | PROTAC
  • Natural Products
    148
    TargetMol | Natural_Products
  • Recombinant Protein
    10
    TargetMol | Recombinant_Protein
  • Isotope Products
    9
    TargetMol | Isotope_Products
  • Disease Modeling
    1
    TargetMol | Disease_Modeling_Products
  • Cell Research
    3
    TargetMol | Cell_Research_Reagents
  • Reference Standards
    32
    TargetMol | Standard_Products
  • ADC/ADC Related
    1
    TargetMol | All_Pathways
  • Oligonucleotides
    1
    TargetMol | All_Pathways
PI3K/Akt/mTOR-IN-2
T605642757804-89-8In house
PI3K/Akt/mTOR-IN-2 is a potent PI3K/AKT/mTOR inhibitor with anticancer effects and selectivity for MDA-MB-231 cells (IC50 2.29 μM). It induces cell cycle arrest and apoptosis in cancer cells.
  • $33
In Stock
Size
QTY
ALK/PI3K/AKT-IN-1
T2063083050831-84-7
ALK/PI3K/AKT-IN-1 (Compound 45) effectively inhibits the proliferation of cancer cell lines A549, H1975, and PC9, with IC50 values of 0.44, 0.83, and 1.51 μM, respectively. This compound enhances the expression of p21 and p27, and decreases the activity of CDK2 and p-Rb, causing cell cycle arrest at the G1 phase. It suppresses the ALK/PI3K/AKT signaling pathway, promotes mitochondrial membrane potential depolarization, and induces apoptosis in A549 cells. Furthermore, ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheres.
  • Inquiry Price
10-14 weeks
Size
QTY
PI3K/Akt/mTOR-IN-4
T209582
PI3K/Akt/mTOR-IN-4 (compound 4r) is a potent inhibitor targeting PI3K/Akt/mTOR pathways and tubulin polymerization. It induces apoptosis and causes cell cycle arrest at the G2/M phase. Additionally, PI3K/Akt/mTOR-IN-4 reduces the expression of p-PI3K, p-Akt, p-mTOR, and β-tubulin.
  • Inquiry Price
Inquiry
Size
QTY
PI3K/Akt/mTOR-IN-6
T215017
PI3K/Akt/mTOR-IN-6 (Compound JW4) is an orally active inhibitor of the PI3K/Akt/mTOR pathway. It induces apoptosis through the mitochondrial pathway and demonstrates significant anti-non-small cell lung cancer activity.
  • Inquiry Price
Inquiry
Size
QTY
PI3K/AKT-IN-1
T629973033069-84-7
PI3K/AKT-IN-1 is a dual PI3K and AKT inhibitor with anti-cancer activity. It inhibits PI3Kγ, PI3Kδ, and AKT, suppressing the PI3K/AKT pathway and inducing caspase 3-dependent apoptosis, suitable for cancer research.
  • $68
In Stock
Size
QTY
PI3K/Akt/mTOR-IN-3
T634552457245-94-0
PI3K/Akt/mTOR-IN-3 is a potent inhibitor of PI3K/Akt/mTOR. PI3K/Akt/mTOR-IN-3 inhibits the migration of MCF-7 cells (IC50: 0.77 μM), HeLa cells (IC50: 1.23 μM) and HepG2 cells (IC50: 4.57 μM). PI3K/Akt/mTOR-IN-3 inhibited the migration of MCF-7 and HeLa cells at a concentration of 4 μM. PI3K/Akt/mTOR-IN-3 blocked the cell cycle in S phase and induced apoptosis.
  • $1,520
6-8 weeks
Size
QTY
PI3K/Akt-IN-C89
T712721195621-75-0
PI3K/Akt-IN-C89 is a novel Inhibitor of the PI3K-Akt Pathway, Inducing Autophagy of Female Germline Stem Cells.
  • $1,520
4-6 weeks
Size
QTY
PI3K/Akt/CREB activator 1
T722272708177-73-3
PI3K/Akt/CREB activator 1 (AE-18) is a selective inducible nitric oxide synthase (iNOS) inhibitor that crosses the blood-brain barrier, reduces infarct size and restores blood supply deficits after ischemia-reperfusion in rats, and is used in studies of vascular dementia and Parkinson's disease.
  • $99
In Stock
Size
QTY
PI3K/AKT-IN-2
T728802684412-41-5
PI3K/AKT-IN-2, a dual inhibitor of PI3K and AKT, prevents the epithelial-mesenchymal transition (EMT) and promotes apoptosis. Additionally, it impedes tubulin polymerization.
  • $1,520
6-8 weeks
Size
QTY
PI3K/Akt/mTOR-IN-5
T89102
PI3K/Akt/mTOR-IN-5 (compound D3), a derivative of Pseudolaric Acid B, exhibits antitumor activity. This compound inhibits excessive proliferation of tumor cells through the PI3K/AKT/mTOR and STAT3/GPX4 pathways. Additionally, PI3K/Akt/mTOR-IN-5 effectively suppresses the EDU positive rate, reduces colony formation, and induces apoptosis (apoptosis) by arresting HCT-116 cells in the S and G2/M phases.
  • Inquiry Price
Inquiry
Size
QTY
PI3K/AKT-IN-4
TN8157
PI3K/AKT-IN-4 (compound 3), a diterpenoid extracted from the roots and rhizomes of Salvia castanea Dielsf., exhibits antitumor properties by inhibiting cell viability and proliferation (IC 50 =4.72 μM) and promoting apoptosis in Hep3B cells. This compound obstructs the G0/G1 phase of the cell cycle, triggers mitochondrial dysfunction, and induces oxidative stress. Moreover, PI3K/AKT-IN-4 combats hepatocellular carcinoma through the inhibition of the PI3K-Akt signaling pathway and by interacting with PARP1 and CDK2 targets.
  • Inquiry Price
Inquiry
Size
QTY
Minocycline hydrochloride
Minocycline HCl
T110113614-98-7
Minocycline hydrochloride (Minocycline HCl) is a tetracycline antibiotic with excellent absorption and tissue penetration that is used for several bacterial infections as well as treatment of acne. Minocycline hydrochloride can cause both an acute hepatitis-like syndrome occurring within 1 to 3 months of starting therapy or a more insidious chronic hepatitis with autoimmune features typically after long-term treatment.
  • $38
In Stock
Size
QTY
TargetMol | Citations Cited
Musk ketone
T565481-14-1
Musk ketone can induce the growth repression and the apoptosis of cancer cells. Musk ketone increases activity of glutathione S-transferase and thus may prove to be useful cancer chemoprotectant.
  • $30
In Stock
Size
QTY
BpV(HOpic)
bpV (HOpic)
T7953722494-26-0
BpV(HOpic) (bpV (HOpic)) is a potent inhibitor of PTEN (IC50 of 14 nM).
  • $39
In Stock
Size
QTY
Cichoric Acid
Dicaffeoyltartaric acid, Chicoric Acid
TL00066537-80-0
Cichoric Acid (Dicaffeoyltartaric acid) is a potent inhibitor of human immunodeficiency virus type-1 (HIV-1) integrase and the replication in tissues. It also a class of cannabinomimetics with CB2 receptor-dependent and independent.
  • $35
In Stock
Size
QTY
TargetMol | Citations Cited
beta-Amyrone
β-Amyron
TN3500638-97-1
beta-Amyrone (β-Amyron) has antifungal activity against Chikungunya virus replication with an EC50 of 86 uM. beta-Amyrone has anti-inflammatory activity through inhibiting the expression of COX-2. beta-Amyrone exhibits anti-α-glucosidase inhibitory activity and moderate AChE activity. β-Amyrone can be used in the research of disease like inflammation, infection, and obesity.
  • $122
In Stock
Size
QTY
Sincalide
SQ19844, Cholecystokinin octapeptide, CCK-8
TP119725126-32-3
Sincalide (CCK-8) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin.
  • $89
In Stock
Size
QTY
TargetMol | Citations Cited
AZD-3463
ALK/IGF1R inhibitor
T19671356962-20-3
AZD-3463 (ALK/IGF1R inhibitor), an orally bioavailable ALK inhibitor (Ki: 0.75 nM), can inhibit IGF1R with equivalent potency.
  • $48
In Stock
Size
QTY
EGCG Octaacetate
T8160148707-39-5
EGCG Octaacetate, a prodrug of EGCG, is utilized to enhance the stability and bioavailability of EGCG in vivo. It has high efficacy, bioavailability, anti-oxidation, and anti-angiogenesis capacities.
  • $37
In Stock
Size
QTY
TargetMol | Citations Cited
Recilisib
ON 01210, Ex-RAD
T13862334969-03-8
Recilisib (ON 01210) is a radioprotectant that activates AKT and PI3K activities in cells.
  • $38
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Nimbolide
T1632425990-37-8
Nimbolide, a triterpenoid derived from neem leaves and flowers, is a natural product and a CDK4/CDK6/NF-κB inhibitor that inhibits multiple signaling pathways including Wnt and PI3K-Akt, possesses antitumor activity, and can induce tumor cell apoptosis.
  • $65
In Stock
Size
QTY
TargetMol | Citations Cited
Alpelisib
BYL-719
T19211217486-61-7
Alpelisib (BYL-719) is a PI3Kα inhibitor (IC50=5 nM) with selective, potent, and oral activity, inhibiting PI3Kβ/γ/δ with low activity (IC50=250/290/1200 nM). Alpelisib demonstrates antitumor activity and specifically targets PIK3CA mutant tumors.
  • $33
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Cytochalasin D
T322922144-77-0
Cytochalasin D is an actin inhibitor, the removal of actin stress fibers is crucial for the chondrogenic differentiation. It may be an inhibitor of some fertilization processes such as sperm penetration or sperm head decondensation. Cytochalasin D inhibit
  • $70
In Stock
Size
QTY
TargetMol | Inhibitor Hot
Taurocholic acid
N-Choloyltaurine
TN225981-24-3
Taurocholic acid (N-Choloyltaurine) is a bile acid involved in fat emulsification, possessing notable biological and immunomodulatory activities. It can inhibit bile duct injury induced by hepatic artery ligation by upregulating VEGF-A expression and protect cholangiocytes from TNF-α-induced damage via a PI3K-mediated pathway, and is commonly used to induce pancreatitis models.
  • $55
In Stock
Size
QTY
TargetMol | Citations Cited